BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 36385707)

  • 21. [Prognostic evaluation value of (18)F-FDG PET-CT in Hodgkin's lymphoma after treatment].
    Wan H; Liu P; Liang Y; Jiang SY; Lyu L; Zhang ZW; Wu N; Liu Y
    Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1275-1281. PubMed ID: 34915636
    [No Abstract]   [Full Text] [Related]  

  • 22. Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy.
    Figura NB; Robinson TJ; Sim AJ; Wang X; Cao B; Chavez JC; Shah BD; Khimani F; Lazaryan A; Davila M; Bachmeier C; Nishihori T; Liu HD; Kim S; Locke FL; Jain MD
    Int J Radiat Oncol Biol Phys; 2021 Dec; 111(5):1145-1154. PubMed ID: 34242714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy.
    Winkelmann M; Blumenberg V; Rejeski K; Bücklein VL; Ruzicka M; Unterrainer M; Schmidt C; Dekorsy FJ; Bartenstein P; Ricke J; von Bergwelt-Baildon M; Subklewe M; Kunz WG
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1406-1413. PubMed ID: 36513818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a radiomic-clinical nomogram for prediction of survival in patients with diffuse large B-cell lymphoma treated with chimeric antigen receptor T cells.
    Zhou Y; Zhang B; Han J; Dai N; Jia T; Huang H; Deng S; Sang S
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11549-11560. PubMed ID: 37395846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma.
    Ceriani L; Martelli M; Gospodarowicz MK; Ricardi U; Ferreri AJ; Chiappella A; Stelitano C; Balzarotti M; Cabrera ME; Cunningham D; Guarini A; Zinzani PL; Giovanella L; Johnson PW; Zucca E
    Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):42-49. PubMed ID: 27839910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic value of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUV
    Li YH; Zhao YM; Jiang YL; Tang S; Chen MT; Xiao ZZ; Fan W; Hu YY; Zhang X
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1311-1321. PubMed ID: 34651231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study.
    Beyar Katz O; Perry C; Grisariu-Greenzaid S; Yehudai-Ofir D; Luttwak E; Avni B; Zuckerman T; Sdayoor I; Stepensky P; Ringelstein-Harlev S; Bar-On Y; Libster D; Sharvit L; Amit O; Greenbaum U; Gold R; Herishanu Y; Benyamini N; Avivi I; Ram R
    Eur J Haematol; 2023 Jul; 111(1):63-71. PubMed ID: 36964939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surveillance Imaging after Autologous Hematopoietic Cell Transplantation Predicts Survival in Patients with Diffuse Large B Cell Lymphoma.
    Savani M; Gencturk M; Shanley R; Cayci Z; Wilke C; Warlick ED; He F; Janakiram M; Weisdorf DJ; Brunstein CG; Bachanova V
    Biol Blood Marrow Transplant; 2020 Feb; 26(2):272-277. PubMed ID: 31669174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early evaluation of CAR-T cell therapy response in R/R DLBCL patients using
    Kitajima K; Yokoyama H; Wada R; Tamaki Y; Yoshihara K; Kaida K; Yoshihara S; Yamakado K
    Hell J Nucl Med; 2024; 27(1):8-15. PubMed ID: 38629814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostication of diffuse large B-cell lymphoma patients with Deauville score of 3 or 4 at end-of-treatment PET evaluation: a comparison of the Deauville 5-point scale and the ΔSUVmax method.
    Ng DZ; Lee CY; Lam WW; Tong AK; Tan SH; Khoo LP; Tan YH; Chiang J; Chang EW; Chan JY; Poon EY; Somasundaram N; Farid H Rashid M; Tao M; Lim ST; Yang VS
    Leuk Lymphoma; 2022 Jan; 63(1):256-259. PubMed ID: 34665693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements.
    Eertink JJ; Arens AIJ; Huijbregts JE; Celik F; de Keizer B; Stroobants S; de Jong D; Wiegers SE; Zwezerijnen GJC; Burggraaff CN; Boellaard R; de Vet HCW; Hoekstra OS; Lugtenburg PJ; Chamuleau MED; Zijlstra JM;
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):943-952. PubMed ID: 34476551
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Burggraaff CN; Eertink JJ; Lugtenburg PJ; Hoekstra OS; Arens AIJ; de Keizer B; Heymans MW; van der Holt B; Wiegers SE; Pieplenbosch S; Boellaard R; de Vet HCW; Zijlstra JM;
    J Nucl Med; 2022 Jul; 63(7):1001-1007. PubMed ID: 34675112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. End-of-treatment
    Allioux F; Gandhi D; Vilque JP; Nganoa C; Gac AC; Aide N; Lasnon C
    Leuk Lymphoma; 2021 Dec; 62(12):2890-2898. PubMed ID: 34219589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-transplantation Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Lymphoblastic Lymphoma is an Independent Prognostic Factor with an Impact on Progression-Free Survival but not Overall Survival.
    Dai N; Liu H; Deng S; Sang S; Wu Y
    Technol Cancer Res Treat; 2021; 20():15330338211056478. PubMed ID: 34806464
    [No Abstract]   [Full Text] [Related]  

  • 37. Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy.
    Voltin CA; Paccagnella A; Winkelmann M; Heger JM; Casadei B; Beckmann L; Herrmann K; Dekorsy FJ; Kutsch N; Borchmann P; Fanti S; Kunz WG; Subklewe M; Kobe C; Zinzani PL; Stelljes M; Roth KS; Drzezga A; Noppeney R; Rahbar K; Reinhardt HC; von Tresckow B; Seifert R; Albring JC; Blumenberg V; Farolfi A; Flossdorf S; Gödel P; Hanoun C
    Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1361-1370. PubMed ID: 38114616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of standardized uptake value on F18-FDG PET/CT in patients with extranodal nasal type NK/T cell lymphoma: A multicenter, retrospective analysis.
    Pak K; Kim BS; Kim K; Kim IJ; Jun S; Jeong YJ; Shim HK; Kim SD; Cho KS
    Am J Otolaryngol; 2018; 39(1):1-5. PubMed ID: 29056243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Value of Pre-Autologous Stem Cell Transplantation PET/CT in Diffuse Large B-Cell Lymphoma: The Deauville Score Is Prognostically Superior to ΔSUVmax.
    Zhang XY; Song L; Wang PJ; Wang L; Li Y; Wang YY; Shi CL
    Acta Haematol; 2020; 143(2):124-130. PubMed ID: 31382264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are dynamic or fixed FDG-PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing autologous haematopoietic stem cell transplantation?
    Campbell BA; Brown R; Lambertini A; Hofman MS; Bressel M; Seymour JF; Wirth A; MacManus M; Dickinson M
    Br J Haematol; 2023 May; 201(3):502-509. PubMed ID: 37015002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.